AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
04/10/2021 – AB Science today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA)